Pinto-Fraga José, Blázquez Arauzo Francisco, Urbano Rodríguez Rubén, González-García María J
Instituto de Oftalmobiología Aplicada, Universidad de Valladolid, Valladolid, Spain; CIBER-BNN, Valladolid, Spain.
Instituto de Oftalmobiología Aplicada, Universidad de Valladolid, Valladolid, Spain.
J Optom. 2015 Jan-Mar;8(1):40-7. doi: 10.1016/j.optom.2014.07.004. Epub 2014 Aug 8.
To evaluate the safety and efficacy of a new multipurpose disinfecting solution (MPDS) with a formulation that includes aloe vera on its composition.
This is a prospective, randomized, double-masked clinical trial with a crossover design that included seven examinations. Two different MPDSs, Avizor Alvera® (study solution) and All Clean Soft® (control solution), each were used for 1 month. Comfilcon A silicone hydrogel contact lenses were used during the trial. The main outcome variables were corneal staining and deposits on the surfaces of the contact lenses. Other parameters including ocular surface response, contact lens wettability, user satisfaction, and adverse events, were analyzed according to the International Organization for Standardization (ISO) 11980:2010 guidance for clinical investigation.
Twenty subjects (10 women, 10 men) (mean age, 27.7±5.6 years; range, 20-41) were included. No differences between both MPDSs were found in the percentage of subjects with corneal staining >0 at day 30 (study: 35%, control: 50%; p=0.46); neither in the percentage of subjects with deposits on the surface of the contact lens >0 at day 30 (study: 26.32%, control: 52.63%; p=0.18). The study MPDS received higher rates in comfort (study: 8.14±1.09, control: 7.94±0.92; p=0.56) and satisfaction at day 30 (study: 8.63±0.91, control: 8.29±0.80; p=0.19), however the scores were not significantly different with the control MPDS.
The clinical trial showed that the study MPDS is safe, efficient, and has acceptable physiologic tolerance, according to the ISO 11980:2010 guidance for clinical investigation.
评估一种新型多功能消毒溶液(MPDS)的安全性和有效性,该溶液配方中含有芦荟。
这是一项前瞻性、随机、双盲的交叉设计临床试验,包括七次检查。两种不同的MPDS,即Avizor Alvera®(研究溶液)和All Clean Soft®(对照溶液),每种使用1个月。试验期间使用Comfilcon A硅水凝胶隐形眼镜。主要结局变量为角膜染色和隐形眼镜表面的沉积物。根据国际标准化组织(ISO)11980:2010临床研究指南,分析了包括眼表反应、隐形眼镜润湿性、用户满意度和不良事件在内的其他参数。
纳入20名受试者(10名女性,10名男性)(平均年龄27.7±5.6岁;范围20 - 41岁)。在第30天角膜染色>0的受试者百分比方面,两种MPDS之间未发现差异(研究组:35%,对照组:50%;p = 0.46);在第30天隐形眼镜表面有沉积物>0的受试者百分比方面也未发现差异(研究组:26.32%,对照组:52.63%;p = 0.18)。研究用MPDS在第30天的舒适度(研究组:8.14±1.09,对照组:7.94±0.92;p = 0.56)和满意度(研究组:8.63±0.91,对照组:8.29±0.80;p = 0.19)方面得分较高,但与对照MPDS相比,得分差异不显著。
根据ISO 11980:2010临床研究指南,该临床试验表明研究用MPDS安全、有效且具有可接受的生理耐受性。